logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics reaches significant technical milestone for its oral dissolvable thin film platform

The firm's German subsidiary Vektor Pharma TF GmbH has now successfully incorporated peptide biosensors into the group's oral dissolvable thin film (ODF) technology

XPhyto Therapeutics Corp. -
The screening tests are for bacterial and viral infectious diseases, including influenza A, scarlet fever and periodontitis

XPhyto Therapeutics Corp (CSE:XPHY) (FSE:4XT) (OTCPINK:XPHYF) revealed Monday that it has reached a technical milestone, which should "unlock a pipeline of potential biosensor screening products".

The group said its German subsidiary Vektor Pharma TF GmbH has now successfully incorporated peptide biosensors into the group's oral dissolvable thin film (ODF) technology.

READ: XPhyto Therapeutics says partner 3a-Diagnostics receives German grant for infectious disease screening tests

In April this year, XPhyto and its diagnostic partner 3a-Diagnostics GmbH (3a) inked a definitive development, technology purchase and licence agreement to include 3a's pathogen-specific biosensors into XPhyto's ODF platform and the pair are now developing biosensors for infectious diseases, including pandemic threats.

The screening tests are for bacterial and viral infectious diseases, including influenza A, scarlet fever and periodontitis. Further pandemic-focused biosensors are in planning and development, specifically for coronavirus (COVID-19) and avian flu (H5N1) and swine flu (H1N1).

"Successful incorporation of 3a's peptide biosensors into Vektor's ODF platform represents a significant technical milestone on the pathway to commercialization," Hugh Rogers, XPhyto CEO said in a statement. "This was a critical step that unlocks a pipeline of potential biosensor screening products."

Vektor and 3a are now reviewing how to optimize the dissolvable thin film technology, including where to place the strip (tongue or cheek), the size, time to dissolve and taste.

Vektor has begun strategic planning for pilot-scale EU GMP test-manufacturing for use in clinical evaluation, said XPhyto.

On June 10 this year, the group revealed that 3a-Diagnostics GmbH and its contract research collaborators had received a grant from the German Federal Ministry of Education and Research (BMBF) which will be used for the infectious disease screening tests.

The €254,200 (US$289,325) grant is part of the KMU-innovativ program for small and medium-sized enterprises that are pioneering innovation and technological progress in Germany, said XPhyto.

Contact the author at [email protected]

Quick facts: XPhyto Therapeutics Corp.

Price: 3.09 CAD

CSE:XPHY
Market: CSE
Market Cap: $167.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

XPhyto Therapeutics partner 3A revives grant from German Ministry of...

XPhyto (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive Vancouver to bring news their German partner 3aDiagnostics and their contract research collaborators, have received a grant from the German Federal Ministry of Education and Research. Roger telling Proactive...

on 12/6/20

2 min read